Tokyo Joe's Cafe / Societe Anonyme/No Pennies Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: jopawa who wrote (60666)	3/10/1999 3:25:00 PM
From: Yo Yo	Read Replies (3) of 119973

IMCL -- Analyst target = $60-$150 per share!!! Now $14 See below.... ...analyst Jim McCamant of the Medical Technology Stock Letter sounds extremely hopeful. The trials produced outstanding results: 14 of the 16 head and neck cancer patients treated with C225 plus radiation showed a 100% tumor regression, as compared with historical rates of 30%-40% for radiation alone. .....A good (valuation) example is IDEC Pharmaceuticals (NASDAQ:IDPH - news) , which has gleaned a market cap of $900 million based on its share of half the profits of Rituxan, a $200 million revenue-per-year drug. Calculating that multiple for ImClone, McCamant says he "finds it hard to believe" sales of C225 will be less than $200 million by 2002, and possibly as high as $500 million. Using the midpoint multiple of 7.5 times revenue, the analyst sees a range of between $1.5 billion and $3.75 billion in ImClone's market capitalization. That nets to a share price range of $60 - $150, a dramatic improvement over the current price of $10 per share. Not bad! Yo Yo

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next